EUCTR2010-020168-39-DE进行中（未招募）不适用
A randomised, double blind, placebo controlled efficacy and safety trial of different doses/dose regimens of FP187 compared to placebo in moderate to severe plaque psoriasis.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients will be entered into this trial only if they meet all of the following criteria:
- •Patients of either sex at least 18 years of age
- •A clinical diagnosis of plaque psoriasis defined as skin areas with erythema, induration and scaling, with a body surface area score of no less than 10% and in total to be scoring at least 10 on the PASI scale.
- •The psoriasis disease have been stable for at least 6 months at randomisation
- •Signed and dated informed consent,
- •Sexually active females of childbearing potential must be either surgically sterile (hysterectomy or tubal ligation) or use a highly effective (failure rate <1%) medically accepted contraceptive method during the trial as well as one month after trial is finished such as:
- •oSystemic contraceptive (oral, implant, injection),
- •oIntrauterine device (IUD) inserted for at least one month prior to study entrance.
- •Willingness and ability to comply with the trial procedures.
- •Patient is beside the psoriasis disease in good general health in the opinion of the Investigator, as determined by medical history, physical examination, vital signs (systolic and diastolic blood pressure [upper limit 145/90] pulse rate [between 50 and 100]), electrocardiogram (ECG), and clinical laboratory parameters (hematology, biochemistry and urinalysis). Minor deviations of laboratory values from the normal range may be accepted, if judged by the Investigator to have no clinical relevance.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will not be enrolled if they meet any of the following criteria:
- •Female patients who are pregnant or breast-feeding or planning to become pregnant up to 7 months from treatment start as well as male patients planning pregnancy with their partner up to 7 months from treatment start or practise unprotected sexual relationship up to 7 months from treatment start.
- •Known allergy to any of the constituents of the product being tested,
- •Pustular forms of psoriasis, erythrodermic or guttate psoriasis
- •Known immunosuppressive diseases (e.g., AIDS/HIV)
- •Presence of another serious or progressive disease which, according to the Investigator may interfere with treatment outcome,
- •Active skin disease such as atopic dermatitis, rosacea, lupus erythematosus, or other inflammatory or infectious skin disease which, according to the Investigator may interfere with treatment outcome,
- •Use of topical medical treatment or UVB treatment during the 2 weeks preceding the baseline visit (Day -5),
- •Use of systemic anti-psoriatic treatment preceding the baseline visit (Day -5):
- •.1Methotrexate, cyclosporine, steroids or PUVA treatment within 4 weeks,
- •.2Biological treatment (efalizumab, adalimumab, infliximab, etanercept) within 12 weeks
- •.3Acitretin within 6 months
- •Treatment with Fumaderm® or other DMF containing products during past 24 weeks prior to baseline visit (Day -5)
- •Discontinuation of previous treatment with Fumaderm® or other DMF containing products due to lack of efficacy or side effects
- •Has within the past 4 weeks prior to baseline visit been treated with drugs influencing the course of the psoriasis such as antimalarial drugs or lithium
- •Has a relevant clinical history of stomach or intestinal problems (eg gastritis or peptic ulcer within the last 10 years )
- •Has liver enzyme measures (AST, ALT,gamma-GT) higher than 2 x UNL
- •Has an estimated Creatinine Clearance (Cockcroft-Gault): < 60 ml/min
- •Has leucopenia (leukocyte count < 3500/mm3) or eosinophilia (count > 750/µl) or lymphopenia (count < 1.02/nl).
- •Has protein in the urine test at screening or baseline visit
- •Participation in another clinical trial during the last month preceding the baseline visit (Day -5) or participation in a trial with treatment of biologicals within 6 months prior to baseline visit.
- •Patients who are involved in the organization of the clinical investigation or are in any way dependant on the investigator or sponsor
研究者
相似试验
招募中
2 期
Homeopathic treatment of geriatric depressioCTRI/2017/03/008078MBHM College Hospital MHM College Hospital The CHM College Hospital
已完成
2 期
Homeopathic treatment of bedwetting in childreCTRI/2022/04/042009D N De Homoeopathic Medical College and Hospital140
进行中（未招募）
不适用
A double-blind, placebo-controlled, randomized efficacy and safety study of levetiracetam extended release formulation (LEV XR), administered as 2 x 500 mg LEV XR tablets once daily as add-on therapy in subjects from 12 to 70 years with refractory epilepsy suffering from partial onset seizuresEUCTR2006-000987-10-FICB S.A.130
已完成
不适用
A randomised, double blind, placebo controlled comparative trial of Ceramide Cream and Ceramide Cleanser in the management of moderate eczema in adultsACTRN12615000782538Ego Pharmaceuticals Pty Ltd100
进行中（未招募）
1 期
An exploratory study of PQ Grass 27600 SEUCTR2020-000408-13-DEAllergy Therapeutics (UK) Ltd.150